Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
- 26 January 2013
- journal article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 71 (4), 893-904
- https://doi.org/10.1007/s00280-013-2080-6
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) PatientsPLOS ONE, 2012
- Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung CancerCancer Research and Treatment, 2012
- Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer — a pilot studyFolia Histochemica et Cytobiologica, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variablesTherapeutic Advances in Medical Oncology, 2011
- Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung CancerCancer Research and Treatment, 2011
- Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung CancerBMC Research Notes, 2010
- Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapyLung Cancer, 2009
- A prognostic model for advanced stage nonsmall cell lung cancerCancer, 2006
- Histological typing of lung and pleural tumours: third editionJournal of Clinical Pathology, 2001